Developing therapeutic agents for the treatment of cancer
An exciting new way to deliver immunotherapy
Investment Overview
Minimum: £1.6m
Technology Stage: early stage
Investment Stage: Raising Investment

Share this

An exciting new way to deliver immunotherapy

Investment Details

Established in 2012 as a spinout from Oxford University. Its aim is to develop therapeutic agents for the treatment of cancer based on the invention of Professor Shisong Jiang – Recombinant Overlapping Peptides (ROP).

Investment Highlights
Register Your Interest
Name(Required)